Mesenchymal stem cells for treating ocular surface diseases.
Mesenchymal stem cells for treating ocular surface diseases.
复制标题
DOI：
10.1186/s12886-015-0138-4
复制
发表时间：
2015-12-17
影响因子：
2
通讯作者：
Kao WW
中科院分区：
文献类型：
--
作者：
Zhang L;Coulson-Thomas VJ;Ferreira TG;Kao WW
间充质干细胞（MSC）已成为再生医学中细胞治疗的一种有前途的工具。它们容易获得，表现出强大的分化能力，并呈现免疫抑制特性，有助于它们在宿主免疫排斥中存活，因为其在同种异体移植中具有巨大的潜在用途。目前正在进行使用MSC的临床试验，包括培养扩增的同种异体和自体MSC，用于治疗一系列常规疗法无法治疗的疾病。大量的研究致力于使用MSC治疗角膜疾病，结果非常有希望。MSC在体外和体内均已成功分化为角膜上皮细胞，但在体内能否分化为角膜上皮细胞尚不确定。然而，迄今为止，很少有研究明确确立了MSC治疗角膜内皮缺损的疗效。目前，MSC的分离和扩增方案的多样性阻碍了细胞治疗能力的评估和治疗方案的进一步发展。因此，未来的研究应制定MSC分离和表征的国际标准。在这篇综述中，我们讨论了MSC治疗眼表疾病的最新进展。
Mesenchymal stem cells (MSC) have become a promising tool for cell therapy in regenerative medicine. They are readily available, demonstrate powerful differentiation capabilities and present immunosuppressive properties that aid them in surviving from host immune rejection for its great potential use in allograft. Currently clinical trials are underway using MSC, both culture-expanded allogeneic and autologous, for the treatment of a range of diseases not treatable by conventional therapies. A vast array of studies has dedicated towards the use of MSC for treating corneal diseases with very promising outcomes. MSC have successfully differentiated into keratocytes both in vitro and in vivo, and corneal epithelial cells in vitro, but it is uncertain if MSC can assume corneal epithelial cells in vivo. However, to date few studies have unequivocally established the efficacy of MSC for treating corneal endothelial defects. Currently, the diversity in protocols of the isolation and expansion of MSC are hindering to the assessment of cell treatment ability and the further development of treatment regimens. Therefore, future studies should develop international standards for MSC isolation and characterization. In this review, we discuss recent advances in MSC for treating ocular surface diseases.